Interpace Biosciences Sees Preliminary Q3 Revenue of $10.1M–$10.4M
The company expects unaudited Q3 2026 revenue of $10.1 million–$10.4 million, up about 11%–14% from Q2 2026 and 15%–18% from Q3 2025, subject to closing and review.
4M for Q3 2026. That would represent growth of approximately 11%—14% from Q2 2026 and approximately 15%—18% from Q3 2025. The figures remain subject to closing and review.